A large genetic study examined the effects of GLP-1 receptor agonists on health outcomes. Researchers used data from over one million participants across three major cohorts, including UK Biobank, FinnGen, and All of Us. This approach uses genetic markers to estimate drug effects without waiting for long-term clinical trials.
The analysis found that genetically linked exposure to these drugs reduced circulating glucose, HbA1c, and body mass index. It also showed a lower risk of developing type 2 diabetes. These results align with known benefits of the medication for blood sugar control and weight management.
However, the study also identified potential downsides. There was an increased risk of acute and chronic pancreatitis, particularly in people aged 50 to 59 or those who drink alcohol. The data also suggested a higher risk of sarcopenia, or muscle loss, with this effect appearing to be causally related to the drug mechanism.